

EFCG welcomes the European Parliament's Commitment to a Strong Critical Medicines Act

The European Fine Chemicals Group (EFCG) welcomes the European Parliament's position on the Critical Medicines Act (CMA), a landmark initiative aimed at strengthening Europe's health security and industrial sovereignty. The adoption of MEP Sokol's report (by a very large majority) marks an important step, confirming the Parliament's commitment to an ambitious CMA that meaningfully reinforces the European Commission's proposal.

EFCG has consistently advocated for a robust CMA that prioritises the highest quality standards, secure supply chains, strategic autonomy, and the resilience of the European manufacturing capacity, in the best interest of all European patients.

To achieve this objective, the CMA must enhance the competitiveness of European manufacturing by recognising the vital and critical role they play in safeguarding the highest quality, reliability and sustainability standards across the medicinal supply chain.

Europe must now set ambitious, measurable objectives to sustain its sovereign manufacturing capabilities and reduce its dependence on third countries for critical medicines **at every stage of the value chain**. Without clear targets, it becomes impossible to assess whether the CMA will deliver on its promises.

EFCG members will continue supporting the inclusion of a bold European preference within the CMA, consistently reflected across other related legislative instruments such as the forthcoming Industrial Accelerator Act and the Public Procurement package.

A high level of ambition should also be maintained regarding strategic projects, backed by simplified permitting procedures and comprehensive funding mechanisms for investments in innovative and sustainable manufacturing processes within the EU.

However, the absence of clarity on dedicated funding and concrete measures remains a critical gap. **We need concrete, enforceable actions derived from the CMA, implemented without delay. Europe cannot afford further hesitation.** Financial instruments should be clearly defined and budget dedicated to the CMA ambitions, starting with the deployment of the competitiveness Fund to support European Manufacturing infrastructure and capacity. Actionable provisions and clear timelines must be preserved to ensure that implementation remains aligned with the CMA's strategic objectives.

We call on Member States and the European Commission to maintain momentum during the upcoming trilogue negotiations and ensure that the CMA delivers on its objectives.

The time for discussion has passed. It is now time to act!

EFCG

Rue Belliard 40 box 15 B-1040 Brussels Belgium
Tel. +32.2.436.9470 efcg@cefic.be
www.efcg.cefic.org